Rituximab: all 1,386 studies that test it
Page 12 of 14. Open to participants first (177), then studies with results posted, then the rest; newest registration first within each.
- Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To TreatmentWithdrawnNCT00845104Phase 2
- Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive LymphomasCompletedNCT00842595Phase 2
- Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell TransplantWithdrawnNCT00833534Phase 2
- Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms MacroglobulinemiaCompletedNCT00832234Phase 2
- Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompletedNCT00831597Phase 2
- Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to TreatmentWithdrawnNCT00829205Phase 1/2
- CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7CompletedNCT00812669Phase 2
- A Feasibility Study of Co-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of ARLCompletedNCT00799136Phase 2
- Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in AdultsStatus unknownNCT00797810Phase 4
- A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's LymphomaCompletedNCT00794638Phase 1
- Haploidentical Stem Cell Transplantation in NeuroblastomaStatus unknownNCT00790413Early Phase 1
- Safety Study of ABT-263 in Combination With Rituximab in Lymphoid CancersCompletedNCT00788684Phase 1
- R-CHOP-B Bevacizumab for Diffuse Large B Cell LymphomaTerminatedNCT00788606Phase 2
- Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell LymphomaCompletedNCT00787969Phase 1
- Allo-hNHL (FluBuCy)CompletedNCT00785330Phase 2
- Comparison Between Rituximab Treatment and General Corticotherapy Treatment in Patients With PemphigusCompletedNCT00784589Phase 3
- Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia GravisCompletedNCT00774462Phase 2
- Zevalin® First Line in Follicular LymphomaStatus unknownNCT00772655Phase 2
- Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL)WithdrawnNCT00758693Phase 2
- Rescue of Steroidogenic Capacity in Adrenocortical Failure Study (RADS)CompletedNCT00753597Phase 4
- Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune CytopeniasCompletedNCT00749112Phase 2/3
- Efficacy Study of Two Treatments in the Remission of VasculitisCompletedNCT00748644Phase 3
- Tolerance and Efficacy of Rituximab in Sjogren's DiseaseCompletedNCT00740948Phase 2/3
- Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell LymphomaCompletedNCT00740415Phase 2
- Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLLCompletedNCT00738829Phase 1/2
- Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin LymphomaCompletedNCT00726700Phase 2
- S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom MacroglobulinemiaWithdrawnNCT00723658Phase 2
- Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin LymphomaCompletedNCT00720135Phase 1
- Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and RituximabCompletedNCT00667329Phase 1
- Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's DiseaseCompletedNCT00664599Phase 2
- Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) LymphomaCompletedNCT00656812Phase 2
- Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCLCompletedNCT00655837Phase 1
- Rituximab Maintenance Versus Observation After First-line Immunochemotherapy by FCR in Older Patients With Chronic Lymphocytic LeukemiaCompletedNCT00645606Phase 3
- Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal TransplantationCompletedNCT00642655Phase 1/2
- Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell LymphomaCompletedNCT00641095Phase 2/3
- Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin LymphomaTerminatedNCT00637832Phase 2
- Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)Status unknownNCT00628238Phase 2
- A Pilot Trial of Rituxan in Refractory Myasthenia GravisCompletedNCT00619671Phase 1/2
- Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic LeukemiaTerminatedNCT00612612Phase 1
- Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell LymphomaCompletedNCT00599170Phase 2
- Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin LymphomaCompletedNCT00598169Phase 1
- Campath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal TransplanationTerminatedNCT00579592Not applicable
- Rituximab for GVHDWithdrawnNCT00578591Phase 2
- Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHLWithdrawnNCT00577161Phase 3
- A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.CompletedNCT00576433Phase 4
- Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent LymphomaCompletedNCT00572013Phase 1/2
- Value of Rituximab in Humoral Chronic Rejection After Renal TransplantationTerminatedNCT00568477Phase 2
- Rituximab for Prevention of Rejection After Renal TransplantationCompletedNCT00565331Phase 2/3
- Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMPCompletedNCT00564512Phase 3
- High-dose Methylprednisolone and Rituximab in High Risk B-CLLCompletedNCT00558181Phase 2
- A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's LymphomaCompletedNCT00556699Phase 1
- Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus ErythematosusCompletedNCT00556192Phase 2
- Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell LymphomaCompletedNCT00556127Phase 2
- An Analysis of Peripheral Blood T Cell Subsets on Rheumatoid ArthritisCompletedNCT00555542Phase 2
- Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at DiagnosisCompletedNCT00553943Phase 2
- Prospective Trial of Rituximab for Primary Pulmonary Alveolar ProteinosisCompletedNCT00552461Phase 2
- Rituximab Treatment of Focal Segmental GlomerulosclerosisWithdrawnNCT00550342Phase 2
- PET Scans in Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and PrednisoneCompletedNCT00544219Not applicable
- Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLLTerminatedNCT00543114Phase 1
- Rituximab in Patients With Relapsed or Refractory TTP-HUSStatus unknownNCT00531089Phase 2
- Efficiency and Tolerance of Rituximab (mabthéra) in Bullous PemphigoidCompletedNCT00525616Phase 3
- A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)CompletedNCT00517049Phase 2
- HD18 for Advanced Stages in Hodgkins LymphomaCompletedNCT00515554Phase 3
- A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell TransplantTerminatedNCT00515138Early Phase 1
- Rituxan With or Without Methotrexate in Psoriatic ArthritisCompletedNCT00509678Phase 1
- Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent LymphomaCompletedNCT00509379Phase 2
- Rituximab and Involved Field Radiotherapy in Early Stage Follicular LymphomaCompletedNCT00509184Phase 2
- Safety and Tolerability of Rituximab in Neuromyelitis OpticaCompletedNCT00501748Phase 1
- A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18CompletedNCT00500058Phase 1
- Cord Blood Expansion on Mesenchymal Stem CellsCompletedNCT00498316Phase 1
- Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic PurpuraCompletedNCT00486421Early Phase 1
- Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple MyelomaCompletedNCT00477815Phase 1
- Rituximab Therapy for Patients on Kidney Transplant Waiting List With Positive Donor Specific Crossmatch to Living DonorWithdrawnNCT00476515Phase 1
- Study of Rituximab to Treat Chronic Renal Transplant RejectionCompletedNCT00476164Phase 4
- Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid MalignanciesTerminatedNCT00473551Phase 1
- Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host DiseaseStatus unknownNCT00472225Phase 2
- B-Lymphocyte Immunotherapy in Islet TransplantationTerminatedNCT00468442Phase 2
- CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's LymphomaTerminatedNCT00455897Phase 2
- Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's LymphomaCompletedNCT00440388Phase 2
- Comparison of High-Dose Chemotherapy + Rituximab and CHOP + Rituximab in High-Risk Follicular LymphomaStatus unknownNCT00435955Phase 3
- Open Label Clinical Trial With Rituximab (MabThera ®) in Ankylosing SpondylitisStatus unknownNCT00432653Phase 2/3
- Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's LymphomaCompletedNCT00428142Phase 2
- Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL)CompletedNCT00427856Phase 2
- Effect of B-cell Depletion in Patients With Primary Sjögren's SyndromeCompletedNCT00426543Phase 2
- Impact of Rituximab on MRI Evidence of Disease Activity in Patients With Moderate to Severe Rheumatoid ArthritisCompletedNCT00425932Phase 2
- Rituximab in Membranous NephropathyCompletedNCT00425217Phase 2/3
- Rituximab Treatment of Graves' Dysthyroid OphthalmopathyCompletedNCT00424151Phase 1/2
- Intrathecal Rituximab in Treating Patients With Recurrent CNS LymphomaCompletedNCT00416923Phase 1
- Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS LymphomaCompletedNCT00416819Not applicable
- Rituximab in the Treatment of Idiopathic Membranous NephropathyCompletedNCT00405340Early Phase 1
- A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Lupus Nephritis Previously Enrolled in Study U2970gWithdrawnNCT00404157Phase 3
- A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13CompletedNCT00400478Phase 3
- Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's LymphomaStatus unknownNCT00397800Phase 1/2
- Safety and Efficacy of Fludarabine and Cyclophosphamide + RituximabCompletedNCT00393107Phase 2
- Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous TreatmentCompletedNCT00392691Phase 1
- Rituximab Combined With Chemotherapy in Burkitt's LymphomaCompletedNCT00388193Phase 2
- Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell TransplantationCompletedNCT00383994Phase 1
- Therapy for Chronic Cold Agglutinin DiseaseCompletedNCT00373594Phase 2
- Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP)CompletedNCT00372892Phase 2
- Trial of Rituximab Given Pre-Transplant to Sensitised Live Donor Kidney RecipientsStatus unknownNCT00371904Phase 2